CME/CE

This Podcast Plus discussion outlines standardized approaches to identifying and managing tardive dyskinesia. It reviews routine screening practices, use of tools such as AIMS, and key symptoms and timing in at-risk patients. The program also addresses post-diagnosis steps, including patient education, treatment considerations, and coordination of multidisciplinary care to support consistent follow-up and clinical management.

Join Drs. Odufalu and Iroku for this Patient-Clinician Connection, a case-based activity focused on optimizing management of inflammatory bowel disease. Through real-world patient dialogues in Crohn’s disease and ulcerative colitis, this program examines clinical and deep remission, along with treat-to-target principles to guide care. Faculty discuss decision-making around biologic de-escalation, as well as identification of mechanistic failure using therapeutic drug monitoring. The activity also reviews guideline-informed therapy selection across mechanisms, incorporating patient-specific factors such as extraintestinal manifestations, reproductive considerations, and treatment preferences to support individualized, steroid-free remission strategies.

This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series focuses on identifying high-risk and underserved patients, advancing LDL-C–centered treatment strategies, and sustaining long-term secondary prevention.

Across the program, faculty highlight guideline-aligned approaches to risk assessment, treatment intensification—including combination lipid-lowering therapy—and ongoing lipid monitoring. Emphasis is placed on coordinated, systems-based care strategies that support adherence, streamline workflows, and improve patient outcomes to help clinicians close care gaps one inning at a time.

This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series focuses on identifying high-risk and underserved patients, advancing LDL-C–centered treatment strategies, and sustaining long-term secondary prevention.

Across the program, faculty highlight guideline-aligned approaches to risk assessment, treatment intensification—including combination lipid-lowering therapy—and ongoing lipid monitoring. Emphasis is placed on coordinated, systems-based care strategies that support adherence, streamline workflows, and improve patient outcomes to help clinicians close care gaps one inning at a time.

This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series focuses on identifying high-risk and underserved patients, advancing LDL-C–centered treatment strategies, and sustaining long-term secondary prevention.

Across the program, faculty highlight guideline-aligned approaches to risk assessment, treatment intensification—including combination lipid-lowering therapy—and ongoing lipid monitoring. Emphasis is placed on coordinated, systems-based care strategies that support adherence, streamline workflows, and improve patient outcomes to help clinicians close care gaps one inning at a time.

This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series focuses on identifying high-risk and underserved patients, advancing LDL-C–centered treatment strategies, and sustaining long-term secondary prevention.

Across the program, faculty highlight guideline-aligned approaches to risk assessment, treatment intensification—including combination lipid-lowering therapy—and ongoing lipid monitoring. Emphasis is placed on coordinated, systems-based care strategies that support adherence, streamline workflows, and improve patient outcomes to help clinicians close care gaps one inning at a time.

This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series focuses on identifying high-risk and underserved patients, advancing LDL-C–centered treatment strategies, and sustaining long-term secondary prevention.

Across the program, faculty highlight guideline-aligned approaches to risk assessment, treatment intensification—including combination lipid-lowering therapy—and ongoing lipid monitoring. Emphasis is placed on coordinated, systems-based care strategies that support adherence, streamline workflows, and improve patient outcomes to help clinicians close care gaps one inning at a time.

This MinuteCE program brings a practical, team-based approach to improving atherosclerotic cardiovascular disease (ASCVD) prevention. Featuring expert multidisciplinary insights from Joseph Englert, MD, and Matt Malachowski, PharmD, this series focuses on identifying high-risk and underserved patients, advancing LDL-C–centered treatment strategies, and sustaining long-term secondary prevention.

Across the program, faculty highlight guideline-aligned approaches to risk assessment, treatment intensification—including combination lipid-lowering therapy—and ongoing lipid monitoring. Emphasis is placed on coordinated, systems-based care strategies that support adherence, streamline workflows, and improve patient outcomes to help clinicians close care gaps one inning at a time.

Oral selective estrogen receptor degraders (SERDs) are rapidly reshaping the treatment landscape in breast cancer, offering targeted treatment approaches that have demonstrated improvements in progression-free survival and expanded options for patients with ER-positive/HER2-negative disease. Recent ASCO data highlighted the growing role of oral SERDs in optimizing treatment sequencing, addressing ESR1 mutations, and supporting personalized care across early-stage and metastatic settings. These therapies may also facilitate more convenient, patient-centered management while advancing precision medicine approaches in breast cancer care.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.

Oral selective estrogen receptor degraders (SERDs) are rapidly reshaping the treatment landscape in breast cancer, offering targeted treatment approaches that have demonstrated improvements in progression-free survival and expanded options for patients with ER-positive/HER2-negative disease. Recent ASCO data highlighted the growing role of oral SERDs in optimizing treatment sequencing, addressing ESR1 mutations, and supporting personalized care across early-stage and metastatic settings. These therapies may also facilitate more convenient, patient-centered management while advancing precision medicine approaches in breast cancer care.

*Please stay tuned for additional content to this activity available for credit. The maximum amount of credit(s) available for the entire activity is 0.50.